[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100538817":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":28,"locations":39,"responsibleParty":59,"collaborators":33,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":9,"officialTitle":65,"acronym":33,"eligibilityCriteria":66,"healthyVolunteers":63,"sex":67,"minAge":68,"maxAge":33,"enrollmentInfo":69,"targetDuration":33,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":33,"overallStatus":41,"whyStopped":33,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Obinutuzumab in Treatment of Fibrillary Glomerulonephritis","EXPERIMENTAL","Patients with biopsy proven fibrillary GN who have \\>1 gram\u002F24 hour of proteinuria and eGFR ≥ 20 ml\u002Fmin\u002FBSA will be treated with Obinutuzumab.",[13],"Drug: Obinutuzumab",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Obinutuzumab","Obinutuzumab 1g IV on day one and 1 g IV on day 15, followed by identical course at month 6.",[9],[21],"Gazyva",[23,26],{"name":24,"affiliation":5,"role":25},"Ladan Zand","PRINCIPAL_INVESTIGATOR",{"name":27,"affiliation":5,"role":25},"Fernando Fervenza, MD",[29,35],{"name":30,"role":31,"phone":32,"phoneExt":33,"email":34},"Nicholas Geroux","CONTACT","507-266-0956",null,"Geroux.nicholas@mayo.edu",{"name":36,"role":31,"phone":37,"phoneExt":33,"email":38},"Corbyn Bendtsen","507-284-0366","Bendtsen.corbyn@mayo.edu",[40],{"facility":5,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-92.4699,44.02163,{"lat":51,"lon":50},[54,56,58],{"name":30,"role":31,"phone":32,"phoneExt":33,"email":55},"geroux.nicholas@mayo.edu",{"name":36,"role":31,"phone":37,"phoneExt":33,"email":57},"bendtsen.corbyn@mayo.edu",{"name":24,"role":25,"phone":33,"phoneExt":33,"email":33},{"type":25,"investigatorFullName":24,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":33,"oldOrganization":33},"Principal Investigator","100538817","phase-2-obinutuzumab-in-treatment-of-fibrillary-glomerulonephritis-100538817",false,"NCT06295770","A Single-Center Phase 2 Open-Label Trial Evaluating the Efficacy and Safety of Obinutuzumab in Treatment of Fibrillary Glomerulonephritis","Inclusion Criteria:\n\n* ≥18 years of age\n* Biopsy proven fibrillary glomerulonephritis\n* Proteinuria \\> 1.0 g\u002F24hrs prior to initiation of immunosuppressive therapy\n* eGFR ≥ 20 ml\u002Fmin\u002FBSA\n\nExclusion Criteria:\n\n* Secondary FGN (due to monoclonal gammopathy, autoimmune disease or malignancy)\n* Presence of a secondary pathology on biopsy (e.g. diabetic nephropathy)\n* Hepatitis B, C or HIV positive\n* Pregnant or breast-feeding\n* Active infection\n* Kidney transplant\n* Anemia with Hgb \\\u003C 8.0 g\u002FdL\n* Thrombocytopenia with platelet count \\\u003C 100'000\n* Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complication\n* Patients who have received cyclophosphamide in the last 6 months\n* Patients who have received ACTH and\u002For mycophenolate mofetil in the last 30 days\n* Patient who are on prednisone therapy at a dose \\> 10 mg\u002Fday in the last 15 days\n* Patients who received rituximab previously with CD20 count of \\\u003C 5 cells\u002Fmicroliter at the time of enrollment\n* For women who are not postmenopausal (greater than or equal to \\[\\>\u002F=\\] 12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and\u002For uterus): agreement to remain abstinent or use two adequate methods of contraception, including at least one method with a failure rate of less than (\\\u003C) 1 percent (%) per year, during the treatment period and for at least 18 months after the last dose of study drug\n* For men: agreement to remain abstinent or use two adequate methods for contraception, including at least one method with failure rate of less than 1% per year during the treatment period and for at least 6 months (180 days) after the last dose of drug","ALL","18 Years",{"count":70,"type":71},20,"ESTIMATED","INTERVENTIONAL",[74],"PHASE2","The purpose of this research is to learn if Obinutuzumab is effective and safe in treating patients with fibrillary glomerulonephritis (FGN).",[77],"Fibrillary Glomerulonephritis","2026-04-09",{"date":80,"type":81},"2026-04-13","ACTUAL",{"date":83,"type":81},"2024-06-24",{"date":85,"type":71},"2026-12",{"name":5,"class":6},1]